New Alzheimer Association AUC, Patisiran Findings from AANEM, Evobrutinib findings from ECTRIMS
Neurology News Network for the week of October 20, 2018.
AveXis Files BLA for AVXS-101, Gene Therapy for SMA Type 1
The gene therapy is also being assessed for long-term safety data, as well as an additional delivery method.
Thomas Leist, MD: Resetting the Immune System With Cladribine
The director of the Comprehensive Multiple Sclerosis Center at Thomas Jefferson University discussed the concept of lymphocyte depletion to reset the immune system.
DBS Shows No Benefit For Younger Patients With Early-Onset Alzheimer
Patients under the age of 65 were not shown to derive benefit from DBS, but researchers noted that this doesn’t mean it is not helpful for older patients.
New Era Arrives for Disease Modification in Multiple Sclerosis
With more than a dozen available therapies, disease-modification in multiple sclerosis is entering a new era of development.
The Low-Down on Stem Cell Tourism for Neurological Diseases
Stem cell tourism is a global problem. The top three conditions marketed by such clinics are MS, PD, and stroke-often peddling false hope to patients who are vulnerable, desperately searching for a cure.
Hideki Garren, MD, PhD: Measuring MS Progression With Floodlight Open
The smartphone application-led program, Floodlight Open, recently initiated in the US and Canada.
Teriflunomide Slows Brain Atrophy In Patients At Risk for MS Conversion
Results suggested that for every 1% of brain volume lost, a 51.7% increase in risk of clinically definite MS conversion was observed.
Searching for Off-Time Relief in Parkinson Disease
Several agents are currently in development geared at the relief of off-time for patients with Parkinson.
Richard Rudick, MD: The CogEval App in Clinical Practice
The goal of the free application is to make cognitive assessments routine in multiple sclerosis treatment.
Remyelination As The Next Frontier in Multiple Sclerosis
The next important area of therapeutic development in MS appears to be in disease damage repair.
Exploring CB1, CB2 in Various Neurological Conditions
Cannabinoids are being explored in a variety of conditions, ranging from Alzheimer disease to migraine.
Alemtuzumab Shows Continuous Long-Term Effect on Multiple Sclerosis
The monoclonal antibody has shown continued success up to 8 years in clinical trials.
Peter Calabresi, MD: Clinically Validating Neurofilament Light
One of the highly debated topics at ECTRIMS 2018 was the use of the investigational biomarker, neurofilament light, in the clinic.
Phase III Study Brings Hope to ALS
A novel mesenchymal stem cell therapy produced intriguing phase II data and has moved into a randomized, pivotal phase III clinical trial.
The Jack-O’-Lantern Sign: A Case Study
Dengue infection predominantly causes arthritis, fever, headache, and rash; hemorrhagic and neurologic manifestations may also result. What was the prognosis for this patient?
Rapid Development of Migraine Therapies Offers New Hope
Physicians offer perspectives on newly approved products to prevent migraine.
When Disease Hijacks the Brain
Learn about the most insightful article Dr Lazzara has ever read in a research journal.
John Corboy, MD: The DISCO-MS Trial
The professor of neurology at Colorado University spoke about the ongoing phase IV trial to determine the safety of DMT discontinuation in MS.
Siponimod NDA Accepted, New Appropriate Use Criteria for Alzheimer Disease Diagnosis, Disease-Modifying Therapy
Neurology News Network for the week of Oct. 12, 2018.
Cell Therapies Offer Hope But Are Often Misused
Cellular therapies have the potential to make a meaningful difference for patients with neurological disorders, if used correctly.
IncobotulinumtoxinA Reduces Sialorrhea Across Neurological Disorders
IncobotulinumtoxinA significantly reduced unstimulated salivary flow rate for patients with sialorrhea.
Evobrutinib Significantly Reduces T1 Gd+ Lesions in Relapsing Multiple Sclerosis
This marks the first time a BTK inhibitor showed a clinical proof-of-concept in relapsing MS.
Fernando Dangond, MD, MBA: Evobrutinib for Relapsing Multiple Sclerosis
The Head of Global Clinical Development in Neurology at EMD Serono provided insight into the therapy's performance in phase IIb.
Thomas Leist, MD: Immune Reconstitution Therapy for Multiple Sclerosis
The director of Thomas Jefferson's Comprehensive Multiple Sclerosis Center spoke about the introduction of this treatment method into MS.
Patisiran Shows Sustained Improvements in Disease Progression for hATTR Amyloidosis
Patisiran maintained improvements in mNIS+7 and rapidly halted neurologic disease progression in hATTR amyloidosis.
Probing Headaches: A Diagnostic Challenge Quiz
What differentiates migraine from underlying intracranial pathology that may require neuroimaging, like tumors, abscesses, aneurysms, or hemorrhages? Test your skills with this 5-question quiz.
Robert J. Fox, MD: Neurofilament Light as a Biomarker of Treatment Response
The staff neurologist at Cleveland Clinic’s Mellen Center for Multiple Sclerosis spoke about the current understanding of the biomarker.
Hideki Garren, MD, PhD: The ORATORIO-HAND Trial in PPMS
The Global Head of Neuroimmunology at Genentech discussed the upcoming phase III trial of ocrelizumab while on-site at ECTRIMS 2018.
Cladribine Tablets Safety Profile Reaffirmed With Long-Term Data
An updated safety analysis of the therapy in patients with relapsing MS, up to 10 years, has shown no new safety signals.
